{"id":"NCT04452318","sponsor":"Regeneron Pharmaceuticals","briefTitle":"COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-13","primaryCompletion":"2021-10-04","completion":"2021-10-04","firstPosted":"2020-06-30","resultsPosted":"2023-05-15","lastUpdate":"2023-05-15"},"enrollment":3303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Healthy Participants"],"interventions":[{"type":"DRUG","name":"REGN10933 + REGN10987","otherNames":["REGN-COV2","Casirivimab","Imdevimab","REGEN-COV™"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"REGN10933 + REGN10987","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objectives:\n\nCohort A:\n\n• To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCR\n\nCohort A and Cohort A1:\n\n• To evaluate the safety and tolerability of REGN10933+REGN10987 following subcutaneous (SC) administration compared to placebo\n\nCohort B • To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing COVID-19 symptoms (broad-term)\n\nCohort B and Cohort B1\n\n• To evaluate the safety and tolerability of REGN10933+REGN10987 following SC administration compared to placebo","primaryOutcome":{"measure":"Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP","timeFrame":"Up to 1 month","effectByArm":[{"arm":"Cohort A: Placebo of R10933 + R10987","deltaMin":7.8,"sd":null},{"arm":"Cohort A: R10933 + R10987","deltaMin":1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":134,"countries":["United States","Moldova","Romania"]},"refs":{"pmids":["37330602","35803290","35713300","35029629","34473343","34347950","34159344","34159343"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":1428},"commonTop":["COVID-19","Asymptomatic COVID-19"]}}